What is the 13F Pro Quality Score for AMIX?

13F Pro ranks Autonomix Medical, Inc. (AMIX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AMIX's current score at https://13fpro.ai/research/AMIX (free sign-up required for the full ranking).

Which hedge funds own the most AMIX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AMIX include GEODE CAPITAL MANAGEMENT,, Mariner,, UBS Group AG. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AMIX as soon as new 13F filings post.

Where does 13F Pro source AMIX data?

All Autonomix Medical, Inc. fundamentals and ownership data come directly from SEC EDGAR. Autonomix Medical, Inc. files with the SEC under CIK 1617867. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AMIX in?

Autonomix Medical, Inc. (AMIX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AMIX research updated on 13F Pro?

AMIX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Autonomix Medical, Inc.(AMIX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1617867 AMIX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

AMIX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Autonomix Medical, Inc. (AMIX), a Healthcare sector company. AMIX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q4 2026), Autonomix Medical, Inc. reports net income of $-2.7M, free cash flow of $-2.9M. Top institutional holders of AMIX by reported 13-F value include GEODE CAPITAL MANAGEMENT,, Mariner,, UBS Group AG, based on the most recent SEC filings. AMIX trades on the Nasdaq exchange and files with the SEC under CIK 1617867. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Autonomix Medical, Inc. directly from SEC EDGAR.

Revenue

Q4 2026

$0.00

Net Income

Q4 2026

$-2.7M

Free Cash Flow

Q4 2026

$-2.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2026

FY23 $0.00FY24 $0.00FY25 $0.00FY26 $0.00

Net Income

-46.5% YoY

$-16.7MFY 2026

FY23 $-2.0MFY24 $-15.4MFY25 $-11.4MFY26 $-16.7M

Operating Income

-47.0% YoY

$-17.0MFY 2026

FY23 $-2.0MFY24 $-12.0MFY25 $-11.6MFY26 $-17.0M

Total Assets

-22.5% YoY

$7.6MFY 2026

FY23 $865.0KFY24 $9.4MFY25 $9.8MFY26 $7.6M

Total Debt

—FY 2026

FY23 $0.00FY24 $0.00FY25 —FY26 —

Op. Cash Flow

-48.7% YoY

$-12.3MFY 2026

FY23 $-1.9MFY24 $-6.6MFY25 $-8.3MFY26 $-12.3M

Metric	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	$0.00	$0.00	$0.00	$0.00
Net Income	$-16.7M -46.5%	$-11.4M +26.0%	$-15.4M -675.2%	$-2.0M
Operating Income	$-17.0M -47.0%	$-11.6M +3.7%	$-12.0M -504.5%	$-2.0M
Total Assets	$7.6M -22.5%	$9.8M +4.2%	$9.4M +987.5%	$865.0K
Total Debt	—	—	$0.00	$0.00
Operating Cash Flow	$-12.3M -48.7%	$-8.3M -25.1%	$-6.6M -256.0%	$-1.9M

AI Insight: AMIX Financial Trends

Pre-revenue medical device company burning cash with equity base eroding; Q3 2025 saw steepest quarterly losses to date.

• Revenue remains at $0M across all periods. Operating losses consistent at $3M per quarter, except Q3 2025 spike to $8M.

• Operating cash burn averaging $3M quarterly; Q3 2025 peaked at $4M. Equity declined from $10M (Q4 2024) to $6M (Q1 2026).

⚠ Q3 2025 operating loss jumped to $8M vs. typical $3M—threefold spike signals potential one-time charge or accelerated burn phase.

⚠ Equity erosion of 40% from Q4 2024 peak ($10M) to Q1 2026 ($6M) at current burn rate; runway increasingly constrained.

AI Insight: AMIX Ratio Trends

Autonomix Medical faces persistent negative equity returns, with ROE deteriorating to -180.9% in Q1 2026 after losses across all recent quarters.

• ROE has remained deeply negative throughout 2025–Q1 2026, ranging from -152.4% to -189.8%, indicating sustained unprofitability.

• Debt-to-equity ratio was minimal at 0.12 in Q4 2024, suggesting limited financial leverage to cushion losses.

⚠ Consecutive quarters of negative ROE with no sign of inflection into profitability; underlying operational metrics (OpMargin, NPM) unavailable for root-cause analysis.

⚠ Most operating and efficiency metrics are not populated; inability to diagnose whether losses stem from gross margin compression or operating expense overruns.

Get alerted when AMIX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Autonomix Medical, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AMIX

GEODE CAPITAL MANAGEMENT, LLC
$68.5K175,621 sh
Mariner, LLC
$25.9K52,910 sh
UBS Group AG
$13.1K33,497 sh
LPL Financial LLC
$12.3K31,435 sh
BANK OF MONTREAL /CAN/
$9.8K25,000 sh
Ikarian Capital, LLC
$7.3K18,688 sh
Tower Research Capital LLC (TRC)
$2.3K5,841 sh
PNC FINANCIAL SERVICES GROUP, INC.
$619.001,588 sh
Investors Research Corp
$78.00200 sh
Virtu Financial LLC
$5.0012,884 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$68.5K	175,621
Mariner, LLC	$25.9K	52,910
UBS Group AG	$13.1K	33,497
LPL Financial LLC	$12.3K	31,435
BANK OF MONTREAL /CAN/	$9.8K	25,000
Ikarian Capital, LLC	$7.3K	18,688
Tower Research Capital LLC (TRC)	$2.3K	5,841
PNC FINANCIAL SERVICES GROUP, INC.	$619.00	1,588
Investors Research Corp	$78.00	200
Virtu Financial LLC	$5.00	12,884

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AMIX on your watchlist

Track score changes the day Autonomix Medical, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AMIX a good stock to buy?

13F Pro's AI-powered analysis of Autonomix Medical, Inc. (AMIX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMIX are available on the AMIX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AMIX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMIX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Autonomix Medical, Inc.'s investment landscape.